Rhythm Pharmaceuticals, Inc. RYTM Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s cash, cash equivalents, and marketable securities?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported cash, cash equivalents, and marketable securities of $278.49M in Q1 2026.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.